DCF Advisers’s Amgen AMGN Stock Holding History

DCF Advisers’s Portfolio AMGN Stock Details AMGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-3,000	Closed	-$806K	–	86
2023 Q3	$806K	Buy	+3,000	New	+$749K	0.44%	49

Other funds holding AMGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

DCF Advisers's AMGN Position: Q1 2026 in Review

DCF Advisers reduced its Amgen (AMGN) stake by 56% in Q1 2026, selling an estimated $2.67M and leaving 6,000 shares worth $2.11M. The position accounts for 0.56% of the portfolio, ranked #41.

DCF Advisers first reported a position in AMGN in Q4 2019 and has held it in 22 quarters since. The position peaked at $4.42M in Q4 2025. 3,130 funds tracked by Wall St. Rank hold AMGN as of Q1 2026.

DCF Advisers held 6,000 shares of Amgen worth $2.11M as of Q1 2026.
DCF Advisers sold 7,500 Amgen shares in Q1 2026, an estimated $2.67M.
Amgen made up 0.56% of DCF Advisers's portfolio in Q1 2026, its #41 holding.
DCF Advisers first reported a position in Amgen in Q4 2019 and has held it in 22 quarters since.
DCF Advisers's Amgen position peaked at $4.42M in Q4 2025.
3,130 funds tracked by Wall St. Rank held Amgen as of Q1 2026.

Based on DCF Advisers's 13F filing for Q1 2026, filed 11 May 2026.